Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma
-
- Hiroyuki Tagawa
- 1Division of Molecular Medicine and
-
- Shinobu Tsuzuki
- 1Division of Molecular Medicine and
-
- Ritsuro Suzuki
- 1Division of Molecular Medicine and
-
- Sivasundaram Karnan
- 1Division of Molecular Medicine and
-
- Akinobu Ota
- 1Division of Molecular Medicine and
-
- Yoshihiro Kameoka
- 1Division of Molecular Medicine and
-
- Miyuki Suguro
- 1Division of Molecular Medicine and
-
- Keitaro Matsuo
- 2Division of Epidemiology, Aichi Cancer Center Research Institute, Aichi;
-
- Motoko Yamaguchi
- 3Second Department of Internal Medicine, Mie University School of Medicine, Mie;
-
- Masataka Okamoto
- 4Internal Medicine, Fujita Health University School of Medicine, Aichi; and Departments of
-
- Yasuo Morishima
- 5Hematology and Chemotherapy and
-
- Shigeo Nakamura
- 6Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan
-
- Masao Seto
- 1Division of Molecular Medicine and
抄録
<jats:title>Abstract</jats:title> <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and exhibits aggressive and heterogeneous clinical behavior. To genetically characterize DLBCL, we established our own array-based comparative genomic hybridization and analyzed a total of 70 cases [26 CD-positive (CD5+) DLBCL and 44 CD5-negative (CD5−) DLBCL cases]. Regions of genomic aberrations observed in >20% of cases of both the CD5+ and CD5− groups were gains of 1q21-q31, 1q32, 3p25-q29, 5p13, 6p21-p25, 7p22-q31, 8q24, 11q23-q24, 12q13-q21, 16p13, 18, and X and losses of 1p36, 3p14, 6q14-q25, 6q27, 9p21, and 17p11-p13. Because CD5 expression marks a subgroup with poor prognosis, we subsequently analyzed genomic gains and losses of CD5+ DLBCL compared with those of CD5−. Although both groups showed similar genomic patterns of gains and losses, gains of 10p14-p15 and 19q13 and losses of 1q43-q44 and 8p23 were found to be characteristic of CD5+ DLBCL. By focusing on the gain of 13q21-q34 and loss of 1p34-p36, we were also able to identify prognostically distinct subgroups among CD5+ DLBCL cases. These results suggest that array-based comparative genomic hybridization analysis provides a platform of genomic aberrations of DLBCL both common and specific to clinically distinct subgroups.</jats:p>
収録刊行物
-
- Cancer Research
-
Cancer Research 64 (17), 5948-5955, 2004-09-01
American Association for Cancer Research (AACR)
- Tweet
キーワード
詳細情報
-
- CRID
- 1362544418952332032
-
- NII論文ID
- 30018590142
-
- ISSN
- 15387445
- 00085472
-
- データソース種別
-
- Crossref
- CiNii Articles